1. PRINCess Trial Prediction of Regression in CIN2

2. Coordinating centre in Christchurch Mainly NZ but Sydney and Melbourne just completing their approval processes Aim to recruit 600 Numbers now over 300 We have 6 in the trial

3. Eligible women have histologically proven CIN 2 Some referrals will be with recurrent LSIL smears Must be able to attend for 6 monthly colposcopy with smear, biopsy and HPV testing for 2 years Loss to follow-up is registered as a serious adverse event

4. If the CIN 2 regresses they will be discharged back to primary care. If CIN 2 is still present at 2 years it is treated CIN 3 is treated at any time in the trial

5. Why is it an important trial? Safety Prevent over-treatment Many countries don’t screen before 25; England, Holland, Australia Primary HPV screening will mean screening from an older age

6. It is hoped we will also get information on HPV types for prevalence data and perhaps for disease severity prediction. Information on lesion size for disease prediction Perhaps some biomarkers for disease prediction

7. Those are all secondary to the primary aim which is to determine the safety of conservative management of CIN 2 in women under 25 years